IP Verse

Genzyme Corporation opposition analysis

COMPANY ANALYSIS

Latest patents of Genzyme Corporation opposed by its competitors

Patent:
EP2976359
Grant Date:
Mar 23, 2022
Title:
Methods For Treating Osteogenesis Imperfecta
Oppositions:
1
Patent:
EP2970843
Grant Date:
Sep 1, 2021
Title:
High-Density Cell Banking Methods
Oppositions:
1
Patent:
EP3047013
Grant Date:
Aug 18, 2021
Title:
Methods And Systems For Processing A Cell Culture
Oppositions:
1
Patent:
EP3137497
Grant Date:
Apr 7, 2021
Title:
Aav Vectors For Retinal And Cns Gene Therapy
Oppositions:
1
Patent:
EP3497207
Grant Date:
Jan 6, 2021
Title:
Methods For Detecting Aav
Oppositions:
2
Patent:
EP3152299
Grant Date:
Nov 20, 2019
Title:
Seed Train Processes And Uses Thereof
Oppositions:
3
Patent:
EP3133070
Grant Date:
Aug 14, 2019
Title:
Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The Patient
Oppositions:
3
Patent:
EP2371361
Grant Date:
Aug 7, 2019
Title:
Methods To Mobilize Progenitor/Stem Cells
Oppositions:
7

Competitors of Genzyme Corporation

ACCORD HEALTHCARE LTD

KONIG SZYNKA TILMANN VON RENESSE

TEVA PHARMACEUTICAL INDUSTRIES LTD.

Want to track Genzyme Corporation?

Feel free to send us a message here and we will get back to you